Illkirch, France

Bruno Gielthen


Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 6(Granted Patents)


Company Filing History:


Years Active: 2008

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Bruno Gielthen: Innovator in Pharmaceutical Compounds

Introduction

Bruno Gielthen is a notable inventor based in Illkirch, France. He has made significant contributions to the field of pharmaceuticals, particularly in the development of novel compounds for medical treatment. His work focuses on addressing various human and animal diseases through innovative chemical solutions.

Latest Patents

Bruno Gielthen holds a patent for a compound titled "2-(3-Aminoaryl)amino-4-aryl-thiazoles for the treatment of diseases." This invention relates to novel compounds that selectively modulate, regulate, and inhibit signal transduction mediated by certain native and/or mutant tyrosine kinases. These kinases are implicated in a variety of diseases, including cell proliferative, metabolic, allergic, and degenerative disorders. The compounds developed by Gielthen are particularly noted for their potency and selectivity as c-kit inhibitors.

Career Highlights

Bruno Gielthen is associated with Ab Science, a company that focuses on the development of innovative therapies for serious diseases. His work at Ab Science has allowed him to contribute to advancements in medical treatments, showcasing his expertise in pharmaceutical innovation.

Collaborations

Bruno has collaborated with notable colleagues such as Marco Ciufolini and Camille Georges Wermuth. These collaborations have further enriched his research and development efforts in the pharmaceutical field.

Conclusion

Bruno Gielthen's contributions to the field of pharmaceuticals through his innovative patents and collaborations highlight his role as a significant inventor. His work continues to impact the treatment of various diseases, showcasing the importance of innovation in medicine.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…